Development of N=1 RNA Therapies in the Netherlands and Europe
After the development of Milasen in the United States, there has been an increase in the development of antisense oligonucleotide therapies for patients with unique mutations.
OTS2022-01-13T18:14:23+00:00November 3rd, 2021|Categories: Featured Webinar, Past Webinars|
After the development of Milasen in the United States, there has been an increase in the development of antisense oligonucleotide therapies for patients with unique mutations.
Oligonucleotide Therapeutics Society
3960 W Point Loma Blvd, Suite H
Box 346
San Diego, CA 92110
info@oligotherapeutics.org
© Copyright 2012 – 2024 | Oligotherapeutics.org | All Rights Reserved | Finfrock Marketing